deltatrials
Terminated OBSERVATIONAL NCT01522170

aHUS Observational Long Term Follow-Up (LTFU)

An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Atypical Hemolytic Uremic Syndrome
Updated 15 times since 2017 Last updated: Feb 22, 2017 Started: Mar 31, 2012 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Remaining patients were offered a similar observational study (Alexion M11-001) to allow for robust, high quality data collection in a larger, single database

Other terminated trials from Alexion Pharmaceuticals, Inc.

More terminations from Alexion Pharmaceuticals, Inc.

Other Atypical Hemolytic Uremic Syndrome trials with similar outcome

Browse all Atypical Hemolytic Uremic Syndrome trials

This observational or N/A phase trial investigates Atypical Hemolytic Uremic Syndrome and is currently terminated or withdrawn. Alexion Pharmaceuticals, Inc. leads this study, which shows 15 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Aug 2017 · 5 months · monthly snapshot~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Apr 2023 · 16 months · monthly snapshot~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated

  4. Dec 2023 — Jul 2024 [monthly]

    Terminated

  5. Apr 2023 — Dec 2023 [monthly]

    Terminated

▶ Show 10 earlier versions

  1. Dec 2021 — Apr 2023 [monthly]

    Terminated

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated

  3. Nov 2020 — Jan 2021 [monthly]

    Terminated

  4. Jun 2018 — Nov 2020 [monthly]

    Terminated

  5. May 2018 — Jun 2018 [monthly]

    Terminated

  6. Apr 2018 — May 2018 [monthly]

    Terminated

    Phase: NA → None

  7. Aug 2017 — Apr 2018 [monthly]

    Terminated NA

  8. Mar 2017 — Aug 2017 [monthly]

    Terminated NA

    Status: Active Not Recruiting → Terminated

  9. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting NA

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting NA

    First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Amsterdam, Netherlands , Atlanta, United States , Bergamo, Italy , Bern, Switzerland , Bordeaux, France , Boston, United States , Caen, France , Cincinnati, United States , Columbus, United States and 43 more locations